Tonix Pharmaceuticals Enrolled First Patient In Phase 2 HORIZON Study Of TNX-102 SL For MDD; Primary Endpoint Is Change In MADRS Total Score At Week 6

Loading news article.

Tonix Pharmaceuticals Enrolled First Patient In Phase 2 HORIZON Study Of TNX-102 SL For MDD; Primary Endpoint Is Change In MADRS Total Score At Week 6 | WAPE

Tonix Pharmaceuticals Enrolled First Patient In Phase 2 HORIZON Study Of TNX-102 SL For MDD; Primary Endpoint Is Change In MADRS Total Score At Week 6

Article summary

Related companies

Comments —